Preclinical evaluation of the gorilla‐derived HAdV‐B AdV‐lumc007 oncolytic adenovirus ‘GoraVir’ for the treatment of pancreatic ductal adenocarcinoma
Open Access
- 24 January 2024
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 18 (5) , 1245-1258
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy which shows unparalleled therapeutic resistance due to its genetic and cellular heterogeneity, dense stromal tissue, and immune-suppressive tumour microenvironment. Oncolytic virotherapy has emerged as a new treatment modality which uses tumour-specific viruses to eliminate cancerous cells. Non-human primate adenoviruses of the human adenovirus B (HAdV-B) species have demonstrated considerable lytic potential in human cancer cells as well as limited preexisting neutralizing immunity in humans. Previously, we have generated a new oncolytic derivative of the gorilla-derived HAdV-B AdV-lumc007 named 'GoraVir'. Here, we show that GoraVir displays oncolytic efficacy in pancreatic cancer cells and pancreatic-cancer-associated fibroblasts. Moreover, it retains its lytic potential in monoculture and co-culture spheroids. In addition, we established the ubiquitously expressed complement receptor CD46 as the main entry receptor for GoraVir. Finally, a single intratumoural dose of GoraVir was shown to delay tumour growth in a BxPC-3 xenograft model at 10 days post-treatment. Collectively, these data demonstrate that the new gorilla-derived oncolytic adenovirus is a potent oncolytic vector candidate that targets both pancreatic cancer cells and tumour-adjacent stroma.Keywords
This publication has 47 references indexed in Scilit:
- Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14Nature Medicine, 2010
- Organotypic Culture Model of Pancreatic Cancer Demonstrates that Stromal Cells Modulate E-Cadherin, β-Catenin, and Ezrin Expression in Tumor CellsThe American Journal of Pathology, 2009
- Insights into adenovirus host cell interactions from structural studiesVirology, 2009
- A CD46-binding Chimpanzee Adenovirus Vector as a Vaccine CarrierMolecular Therapy, 2007
- RB and cell cycle progressionOncogene, 2006
- Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targetingCancer Gene Therapy, 2006
- CD46 is a cellular receptor for group B adenovirusesNature Medicine, 2003
- Coxsackievirus–adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expressionCancer Gene Therapy, 2001
- A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivoOncogene, 2000
- Coxsackie and adenovirus receptor (CAR)-dependent and major histocompatibility complex (MHC) class I-independent uptake of recombinant adenoviruses into human tumour cellsGene Therapy, 1999